Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor

Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor

Background: Single-agent amrubicin chemotherapy is a key regimen, especially for small cell lung cancer (SCLC); however, it can cause severe myelosuppression. Purpose: The purpose of this study was to determine the real-world incidence of febrile neutropenia (FN) among patients treated with single-a...

Full description

Bibliographic Details
Main Authors: Yosuke Dotsu, Hiroyuki Yamaguchi, Minoru Fukuda, Takayuki Suyama, Noritaka Honda, Yasuhiro Umeyama, Hirokazu Taniguchi, Hiroshi Gyotoku, Shinnosuke Takemoto, Ryuta Tagawa, Ryosuke Ogata, Hiromi Tomono, Midori Shimada, Hiroaki Senju, Katsumi Nakatomi, Seiji Nagashima, Hiroshi Soda, Hiroaki Ikeda, Kazuto Ashizawa, Hiroshi Mukae
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Journal of Clinical Medicine
Subjects:
amrubicin
chemotherapy
granulocyte colony-stimulating factor
febrile neutropenia
lung cancer
Online Access:https://www.mdpi.com/2077-0383/10/18/4221

Internet

https://www.mdpi.com/2077-0383/10/18/4221

Similar Items